Status:
UNKNOWN
Ivermectin Nasal Spray for COVID19 Patients
Lead Sponsor:
Tanta University
Conditions:
Covid19
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
The global escalation of COVID19 pandemic has put the health care system under pressure with urgent need for treatment. In the absence of vaccine and approved drug against SARS-COV2 over the past 6 mo...
Detailed Description
Ivermectin is a well-known FDA-approved pan antiparasitic drug with high safety profile and potential therapeutic effects against COVID 19. It has been previously investigated as an antiviral agent. I...
Eligibility Criteria
Inclusion
- mild to moderate severity who are confirmed to be positive for SARS COV 2.
Exclusion
- patients with severe form of COVID-19 or those who are on ventilatory support or those with cytokine storm
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04510233
Start Date
September 1 2020
End Date
December 1 2020
Last Update
August 12 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.